Related Experiment Videos
Immunomodulatory peptides from IgSF proteins: a review
Mythily Srinivasan1, Roger W Roeske
1Department of Oral Pathology, Indiana University School of Dentistry, Indianapolis, IN 46268, USA. mysriniv@iupui.edu
Current Protein & Peptide Science
|April 28, 2005
Summary
Immunoglobulin superfamily (IgSF) proteins utilize unique CDR-like regions for specific interactions. Designing peptide mimetics targeting these regions offers a promising therapeutic strategy for various diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Immunoglobulin (Ig) domains are conserved in cell surface proteins, resisting proteolysis and mediating diverse functions.
- The Immunoglobulin Superfamily (IgSF) comprises over 2% of human genes, playing critical roles in growth, signaling, and adhesion.
- IgSF proteins exhibit high specificity in receptor-ligand interactions, analogous to antibody complementarity determining regions (CDRs).
Purpose of the Study:
- To review the design of IgSF peptide analogs as therapeutic agents.
- To explore the rationale for targeting IgSF protein-protein interactions.
- To discuss the functional efficacy and clinical benefits of IgSF-targeted peptide antagonists.
Main Methods:
- Leveraging theoretical, structural, and functional data for drug design.
- Mapping receptor/ligand binding epitopes onto small peptides.
- Developing peptide mimetics that perturb specific IgSF interactions.
Main Results:
- CDR-like regions in IgSF proteins are key determinants of binding specificity.
- Peptide antagonists designed using CDR-like regions show therapeutic potential.
- Numerous peptide antagonists have demonstrated efficacy in preclinical animal models.
Conclusions:
- IgSF protein-protein interactions are viable therapeutic targets.
- Peptide-based mimetics offer a promising approach for modulating IgSF functions.
- Further development of IgSF peptide analogs could lead to significant clinical benefits.